Clinical Trial Update: Individual Molecular MRD Monitoring for MDS Patients After Allo-SCT

View source ↗

Summary

Completed clinical trial evaluating individual molecular measurable residual disease (MRD) monitoring in patients with myelodysplastic syndrome after allogeneic…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndrome

Snippet

Sponsor: Nordic MDS Group | Conditions: MDS, SCT | Status: COMPLETED